福辛普利联合通心络胶囊对心衰患者心功能及IL-17,CRP水平的影响

目的:探讨福辛普利联合通心络胶囊对心衰患者心功能及IL-17、CRP水平的影响。方法:108例心力衰竭患者(CHF)依据随机数字表法分为两组:对照组采用福辛普利治疗,观察组采用福辛普利联合通心络胶囊治疗,比较两组患者治疗前后心功能和细胞因子水平变化。结果:观察组治疗总有效率(51例,94.4%)显著高于对照组(41例,75.9%)(x~2=7.34,P=0.01);两组患者治疗后各项心功能指标(LVESV、LVEDD、LVEF、CO、CI、SV、LVMI)较治疗前显著改善(P0.05),但观察组治疗后LVESV、LVEDD、LVEF、CO、CI、SV值显著优于对照组,差异显著(P0.05);心衰患者经治疗之后BNP、IL-17和CRP均显著下降,但观察组治疗后各细胞因子水平显著低于对照组(P0.05);观察组与对照组不良反应率(11.1%与14.8%)无统计学差异(P0.05)。结论:福辛普利联合通心络胶囊能够有效改善患者心功能,降低血清IL-17和CRP水平,具有较好的治疗效果。

Effects of Fosinopril Combined with Tongxinluo Capsules on Heart Function, IL-17 and C-reactive Protein Levels of Heart Failure Patients

Objective:To investigate the effects of Fosinopril plus Tongxinluo on the heart function and IL-17 and CRP levels of patients with heart failure.Methods:108 cases of patients with heart failure (CHF) treated in our hospital were randomly divided into two groups. The control group got fosinopril treatment, while observation group got joint treatment of fosinopril and Tongxinluo. Compared the cardiac function and cellular changes in cytokine levels of patients before and after treatment.Results:The total effective rate of observation group (51 cases, 94.4%) was significantly higher than that of control group (41 cases, 75.9%) (x2=7.34, P=0.01). After treatment, the cardiac function (LVESV, LVEDD, LVEF, CO, CI, SV, LVMI) in both groups were significantly improved, as compared with before treatment (P<0.05). But the values of LVESV, LVEDD, LVEF, CO, CI, SV was significantly better in observation group than in the control group, with significant difference (P<0.05). After treatment, the levels of BNP, IL-17 and CRP were significantly decreased in patients with heart failure, but the levels of various cytokines in the observation group were significantly lower than in the control group (P <0.05). There was no significant difference in adverse reaction rates between observation group and control group (11.1%and 14.8%) (P> 0.05).Conclusion:Fosinopril combined with Tongxinluo capsule can improve cardiac function and reduce serum levels of CRP and IL-17, and have a better therapeutic effect.